Neuren Pharmaceuticals (NURPF) Stock Price, News & Analysis

Company Overview

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome. In March 2023, trofinetide received regulatory approval in the United States under the trade name Daybue for the treatment of Rett syndrome in pediatric patients. Neuren’s preclinical pipeline also includes NNZ-2591, a second-generation molecule targeting Angelman syndrome and other neurodevelopmental conditions. These programs leverage the company’s expertise in peptide biology and neuroinflammation.

Founded in 1998 as a spin-out from Australia’s Royal Children’s Hospital and affiliated research institutes, Neuren has established partnerships to support clinical development and commercialization. The company collaborates with international regulatory bodies and contract research organizations to conduct Phase II and Phase III studies across North America, Europe and Australia. Headquartered in Melbourne, Neuren draws on a team of experienced drug development professionals to advance its mission of transforming the lives of patients with serious neurological disorders.

Key Stats

• Today's Range: C$13.46 to C$13.46
• 50-Day Range: C$8.48 to C$13.46
• 52-Week Range: C$7.70 to C$14.80
• Volume: N/A
• Average Volume: 808 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NURPF
• CIK: N/A
• Web: www.neurenpharma.com
• Phone: (139) 092-0480
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A